Levobupivacaine

Drug Profile

Levobupivacaine

Alternative Names: (S)-bupivacaine; Bupivacaine, (S); Chirocaine; D 1249; Popscaine

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator UCB
  • Developer Maruishi Pharmaceutical; Purdue Pharma; UCB
  • Class Analgesics; Anilides; Local anaesthetics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaesthesia; Pain; Postoperative pain

Most Recent Events

  • 05 Jan 2005 Celltech Group has been acquired by UCB
  • 17 Mar 2003 A case report has been added to the adverse events section
  • 25 Jan 2002 Launched for Anaesthesia in Australia (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top